William Quinn Sells 9,132 Shares of Bolt Biotherapeutics (NASDAQ:BOLT) Stock

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) CEO William Quinn sold 9,132 shares of the company’s stock in a transaction dated Friday, September 18th. The stock was sold at an average price of $3.24, for a total value of $29,587.68. Following the sale, the chief executive officer owned 25,384 shares of the company’s stock, valued at approximately $82,244.16. This trade represents a 26.46% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Bolt Biotherapeutics Stock Up 0.8%

Shares of NASDAQ BOLT traded up $0.03 during mid-day trading on Monday, reaching $3.59. 22,454 shares of the company traded hands, compared to its average volume of 27,365. The company’s fifty day moving average is $3.84 and its two-hundred day moving average is $4.29. The company has a debt-to-equity ratio of 1.47, a quick ratio of 2.61 and a current ratio of 2.61. Bolt Biotherapeutics, Inc. has a fifty-two week low of $3.10 and a fifty-two week high of $7.20. The stock has a market cap of $6.93 million, a PE ratio of -0.22 and a beta of 1.09.

Bolt Biotherapeutics (NASDAQ:BOLT) last posted its earnings results on Tuesday, August 11th. The company reported ($4.57) earnings per share for the quarter, missing the consensus estimate of ($3.39) by ($1.18). Bolt Biotherapeutics had a negative return on equity of 126.23% and a negative net margin of 611.47%.The company had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.50 million. On average, analysts expect that Bolt Biotherapeutics, Inc. will post -11.1 earnings per share for the current year.

Analyst Ratings Changes

BOLT has been the topic of a number of research analyst reports. HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of Bolt Biotherapeutics in a research note on Thursday, May 28th. Rodman & Renshaw assumed coverage on shares of Bolt Biotherapeutics in a research report on Thursday, May 28th. They set a “buy” rating and a $22.00 target price for the company. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a report on Friday, July 17th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Bolt Biotherapeutics presently has a consensus rating of “Hold” and an average price target of $14.50.

Hedge Funds Weigh In On Bolt Biotherapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Nan Fung Group Holdings Ltd bought a new stake in Bolt Biotherapeutics in the 2nd quarter valued at $19,250. Renaissance Technologies LLC increased its holdings in shares of Bolt Biotherapeutics by 40.3% during the 1st quarter. Renaissance Technologies LLC now owns 77,225 shares of the company’s stock worth $312,000 after purchasing an additional 22,200 shares during the period. Finally, T3 Companies LLC bought a new position in shares of Bolt Biotherapeutics during the 4th quarter worth about $208,000. Institutional investors own 86.70% of the company’s stock.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s platform is designed to stimulate the body’s innate and adaptive immune systems to recognize and attack tumor cells.

Bolt’s technology includes Boltbody™ immune-stimulating antibody conjugates, or ISACs. These therapies are intended to combine the targeting capabilities of antibodies with immune-activating components that can recruit and enhance the activity of immune cells within the tumor microenvironment.

The company’s development programs have included BDC-1001, an investigational HER2-targeted ISAC for the treatment of HER2-expressing solid tumors, and BDC-3042, an investigational antibody intended to activate macrophages through the Dectin-2 pathway.